Ellen Cavaleri
Investor Relations Contact at LYRA THERAPEUTICS, INC.
Profile
Ms. Ellen Cavaleri is a Senior VP-Investor Relations & Communications at Lyra Therapeutics, Inc. Ms. Cavaleri was previously employed as an Investor Relations Contact by Kadmon Holdings, Inc. She received her undergraduate degree from Vanderbilt University and an MBA from New York University.
Ellen Cavaleri active positions
Companies | Position | Start |
---|---|---|
LYRA THERAPEUTICS, INC. | Investor Relations Contact | 2021-12-31 |
Former positions of Ellen Cavaleri
Companies | Position | End |
---|---|---|
KADMON HOLDINGS, INC. | Investor Relations Contact | - |
Training of Ellen Cavaleri
Vanderbilt University | Undergraduate Degree |
New York University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
LYRA THERAPEUTICS, INC. | Health Technology |
Private companies | 1 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Ellen Cavaleri